Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (As2O3,)

被引：0
|
作者：
Zhang, T [1 ]
Westervelt, P [1 ]
Hess, JL [1 ]
机构：
[1] Univ Washington, Sch Med, St Louis, MO USA
来源：
LABORATORY INVESTIGATION | 1999年 / 79卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
876
引用
收藏
页码：150A / 150A
页数：1
相关论文
共 50 条
  • [1] Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3)
    Zhang, T
    Westervelt, P
    Hess, JL
    MODERN PATHOLOGY, 2000, 13 (09) : 954 - 961
  • [2] The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia
    Zhang, P
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 1999, 13 (04): : 195 - 200
  • [3] Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL).: The MD Anderson experience.
    Lazo, G
    Cortes, J
    O'Brien, S
    Estey, E
    Thomas, D
    Kantarjian, H
    BLOOD, 2001, 98 (11) : 595A - 596A
  • [4] Arsenic trioxide: Pharmacokinetics in acute promyelocytic leukemia (APL) patients
    Ghiuzeli, Cristina Maria
    Calabro, Anthony
    Saunders, Randall Jesse
    Budman, Daniel R.
    Styblo, Miroslav
    Devoe, Craig E.
    Allen, Steven L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Western study of arsenic trioxide (As2O3) in patients with relapsed and/or refractory acute promyelocytic leukemia
    Soignet, SL
    Maslak, P
    Chen, YW
    Calleja, E
    Pandolfi, PP
    Scheinberg, DA
    Warrell, RP
    ANNALS OF ONCOLOGY, 1998, 9 : 176 - 176
  • [6] Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL) .1. As2O3 exerts dose-dependent dual effects on APL cells
    Chen, GQ
    Shi, XG
    Tang, W
    Xiong, SM
    Zhu, J
    Cai, X
    Han, ZG
    Ni, JH
    Shi, GY
    Jia, PM
    Liu, MM
    He, KL
    Niu, C
    Ma, J
    Zhang, P
    Zhang, TD
    Paul, P
    Naoe, T
    Kitamura, K
    Miller, W
    Waxman, S
    Wang, ZY
    deThe, H
    Chen, SJ
    Chen, Z
    BLOOD, 1997, 89 (09) : 3345 - 3353
  • [7] Clinical observations on arsenic trioxide (As2O3) and all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
    Ma, J
    Liu, JW
    Chen, LY
    Liang, H
    Zhang, Y
    BLOOD, 1998, 92 (10) : 483A - 483A
  • [8] Durable molecular remission in two acute promyelocytic leukemia (APL) patients treated with arsenic trioxide at first molecular relapse.
    Douer, D
    Ramezani, L
    Watkins, K
    Louie, R
    Tallman, MS
    BLOOD, 2005, 106 (11) : 525A - 525A
  • [9] The in vitro study of apoptosis induced with arsenic trioxide (As2O3) and other Chinese medications in acute promyelocytic leukemia (APL) and chronic myelocytic leukemia (CML).
    Liu, JW
    Jun, M
    Ying, W
    BLOOD, 1998, 92 (10) : 193B - 193B
  • [10] Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line
    Noh, Eui-Kyu
    Kim, Hawk
    Park, Min Jae
    Baek, Jin Ho
    Park, Jae-Hoo
    Cha, Seung Joo
    Won, Jong-Ho
    Min, Young Joo
    LEUKEMIA RESEARCH, 2010, 34 (11) : 1501 - 1505
12345